Switching is normal in this market. Prices move, sellers disappear, a plan ends, a molecule becomes unavailable — and the assumption behind every switch is that the new drug will do what the headline says it does. For someone who has taken one of these before, it will not, and this study puts a number on the difference — one that sits underneath the discontinuation figures in two-thirds stop within a year.
What was compared
Researchers built matched cohorts from electronic health records of adults with type 2 diabetes starting either drug, splitting them by whether they had used a GLP-1 before[1]. Each naive cohort held 10,702 matched patients and each experienced cohort 5,577.
Weight was recorded for far fewer: 454 tirzepatide and 432 semaglutide patients among the naive, and 296 and 224 among the experienced. Those are the numbers behind the weight results, and they are much smaller than the matched cohorts they came from.
What it found
Among people for whom this was a first GLP-1, twelve-month weight change was 10.2 kg on tirzepatide against 6.1 kg on semaglutide. Among those who had used one before, it was 7.9 kg against 3.7 kg. HbA1c moved the same way: −1.3% against −0.9% for the naive, and −0.9% against −0.6% for the experienced (p<0.001 throughout).
What it cannot establish
Why. A cohort study can show that prior exposure predicts a smaller subsequent change and cannot say whether that is physiology, or the fact that the easy weight has already gone, or that people who switch differ from people who do not. All three are plausible and none is tested here.
It is also a diabetes population rather than a weight-loss one, and it is matched rather than randomized — the same limit as every observational comparison, set out in a number too good to use.
What it means before changing anything
That the case for switching has to rest on price, availability or tolerability rather than on expecting the new drug to deliver what the first one did not. The premium between the two molecules at a given seller is set out in what the other molecule costs, and the severe side-effect profiles were indistinguishable in the largest head-to-head comparison, covered in paying more for fewer side effects.
If the reason to switch is cost, that is a good reason and the arithmetic is in what a GLP-1 actually costs. If the reason is disappointment, this study suggests the second attempt starts from a lower ceiling.